Ginkgo Bioworks Holdings Operating Income 2020-2023 | DNA

Ginkgo Bioworks Holdings operating income from 2020 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Ginkgo Bioworks Holdings Annual Operating Income
(Millions of US $)
2022 $-2,209
2021 $-1,828
2020 $-137
2019 $-72
Ginkgo Bioworks Holdings Quarterly Operating Income
(Millions of US $)
2023-03-31 $-216
2022-12-31 $-234
2022-09-30 $-653
2022-06-30 $-647
2022-03-31 $-675
2021-12-31 $-1,685
2021-09-30 $-27
2021-06-30 $-60
2021-03-31 $-57
2020-12-31
2020-09-30 $-34
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.379B $0.478B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.942B 8.43
GSK (GSK) United Kingdom $69.839B 9.75
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.584B 22.35
Arcus Biosciences (RCUS) United States $1.536B 0.00
Biohaven (BHVN) United States $1.482B 0.00
Emergent Biosolutions (EBS) United States $0.416B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.191B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00